Adma Biologics reported $124.56M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Adma Biologics USD 124.56M 11.46M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
BioCryst Pharmaceuticals USD 96.97M 58M Sep/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Novavax USD 222.46M 31M Sep/2026
Omeros USD 1.9M 2.36M Jun/2025
Takeda JPY 418.53B 42.45B Sep/2026